ClinicalTrials.gg
CompletedNCT02799745ENACTUpdated Dec 6, 2024Results posted

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Phase 2 interventional study of Enzalutamide and Active Surveillance in Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Completed at 54 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
24th of 125
227 · median 52
Started
2016
with 8 others
Phase 2
65 of 125
8 open now
Registered
64th of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Global Development, Inc.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 24th largest by enrollment, is one of 9 that started in 2016, is one of 65 in phase 2, and was the 64th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.

Read the detailed description

This was a multicenter, randomized, open label exploratory study, conducted in the US and Canada, evaluating the efficacy and safety of enzalutamide for extension of time to prostate cancer progression (pathological or therapeutic) in patients with clinically localized, histologically proven prostate cancer that is categorized as low risk or intermediate risk and who were under AS.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Therapeutic Cancer Progression
  • Pathological Cancer Progression
  • Enzalutamide
  • Prostate Cancer
  • Active surveillance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the prostate diagnosed (with ≥10 core ) within 6 months of screening. The biopsy that was used for this diagnosis must be submitted for central pathology review.
  • Prostate cancer categorized (as determined by central pathology review) as low risk is defined as T1c-T2a, PSA\<10, N0, M0 (or presumed N0, M0 if CT/bone scan not done due to low risk of ), GS ≤ 6, status ≤2 and estimated >5 years OR intermediate risk is defined as T2b-T2c, PSA\<20, N0, M0 (or presumed N0, M0 if CT/bone scan not done), GS ≤7 (3+4 pattern only), ECOG status ≤ 2 and estimated life expectancy > 5 years. Prostate cancer categorized (as determined by central pathology review) to the very low risk category (T1c, GS ≤6, PSA \<10 ng/mL, fewer than 3 prostate biopsy cores positive,

    ≤50% cancer in any core, PSA density \<0.15 ng/mL/g) is not included.

  • Ability to swallow study drugs and to comply with study requirements throughout the study
  • Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures
  • Throughout study, male subject and a female partner who is of must use two acceptable methods of (one of which must include a condom barrier method of contraception) starting at screening and continuing throughout the study period and for three months after the final study drug administration. Two acceptable methods of birth control thus include the following:

    1. Condom (barrier method of contraception) AND
    2. One of the following is required:

    i. Established use of oral, injected or implanted hormonal methods of contraception by the female partner; ii. Placement of an intrauterine device or intrauterine system by the female partner; iii. Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam / gel / film / cream / suppository by the female partner; iv. Tubal ligation in the female partner.

  • Must not donate sperm starting at screening throughout the study period and for 90 days after the final study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer
  • Very low risk category (T1c, GS ≤6, PSA \<10 ng/mL, fewer than 3 prostate cores positive, ≤50% cancer in any core, PSA density \<0.15 ng/mL/g)
  • Prior transurethral resection of the prostate or prior transurethral microwave thermotherapy of the prostate
  • Use of oral within 1 month of screening
  • Use of 5 alpha reductase inhibitor within 1 month of screening or total use, within the last two years prior to screening, of >3 months
  • Presence of disease
  • History of seizure or any condition that may predispose to seizures at any time in the past. History of loss of consciousness or within 12 months of screening
  • \< 1,500/μL, count \< 100,000/μL, or \< 6.2 mmol/L (10 g/dL) at screening
  • Total >1.5 times the (ULN) or (ALT) or aspartate aminotransferase (AST) ≥ 2.5 X ULN at screening
  • Creatinine > 177 μmol/L (> 2 mg/dL) at screening
  • Albumin \< 30 g/L (3.0 g/dL) at screening
  • Major surgery within 4 weeks prior to Randomization Visit
  • cardiovascular disease including:

    1. Myocardial infarction or uncontrolled angina within 6 months
    2. Congestive heart failure (NYHA) class 3 or 4
    3. History of clinically significant ventricular arrhythmias
    4. History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
    5. Hypotension as indicated by systolic blood pressure \< 86 millimeters of mercury (mm Hg) at screening
    6. Bradycardia as indicated by a heart rate of \< 45 beats per minute on the screening (ECG) and on physical examination
    7. Uncontrolled hypertension as indicated by at least 2 consecutive measurements of a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the Screening Visit
  • Known to enzalutamide or any of its components.
  • Subject has received therapy within 28 days or 5 half lives, whichever is longer, prior to screening
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Active comparator
    Enzalutamide

    Participants received 160-milligrams (mg) enzalutamide administered as four 40-mg capsules, orally once daily for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow-up period, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).

    Drug: Enzalutamide

  • Other
    Active Surveillance (AS)

    Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).

    Other: Active Surveillance

Interventions

  • Oral

    Also known as: MDV3100, Xtandi

  • OtherActive Surveillance
06

What researchers measure

Primary outcomes

  1. Time to Prostate Cancer Progression

    Time to cancer prostate progression (pathological or therapeutic): time (in months) from date of randomization until the date of cancer progression (pathological or therapeutic). Pathological progression: increase in primary or secondary Gleason pattern by greater than or equal (\>=) 1 or higher proportion of cancer positive cores (\>=15 percent \[%\] increase). Therapeutic progression: earliest occurrence of primary therapy for prostate cancer (prostatectomy/radiation/focal therapy/systemic therapy). Medians and 95% CIs were calculated with the Kaplan-Meier (KM) method. Participants with no cancer progression at the time of study completion, discontinuation or death were censored at the last assessment date. Participants switching therapy during the study were censored at the time of the initial therapy switch, and participants discontinuing therapy were censored at the time of study discontinuation.

    Time frame: From the date of randomization until the date of the cancer progression (pathological or therapeutic) (up to study completion date, 28 Aug 2020; approximately 50 months)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE: any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily had a causal relationship with treatment. An abnormality identified during a medical test: an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of investigator. An AE: serious if it resulted in any of the following outcomes: Death, was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs: assessed by investigator as AEs whose relationship to study drugs could not be ruled out.

    Time frame: From date of first dose of enzalutamide or randomization until end of study (up to study completion date, 28 Aug 2020; approximately 50 months)

  2. Percentage of Participants Reported Negative Biopsies for Cancer

    Percentage of Participants who reported negative biopsies for cancer were reported.

    Time frame: At the end of months 12 and 24

  3. Change From Baseline in Percent of Cancer Positive Cores at Month 12 and 24

    Percent positive cores were calculated using the number of systemically sampled prostate regions and any targeted regions with at least 1 positive core divided by the total number of systematically sampled regions and targeted regions. This implied that despite the number of samples within a given systematic or targeted region, any positive core indicated that region as positive.

    Time frame: Baseline, months 12 and 24

  4. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was defined as time in months from the date of randomization or first dose enzalutamide untill date of PSA progression (secondary rise in serum PSA \>=25% above baseline or \>=25% above nadir or absolute increase \>= 2 nanogram per mililiter \[ng/mL\]). Participants with no PSA progression at the time of trial completion, discontinuation or death were censored at the last assessment date. Additionally, participants switching therapy during the study were censored at the time of the initial therapy switch, and participants discontinuing therapy were censored at the time of study discontinuation. Medians and 95% CIs were calculated with the KM method.

    Time frame: From date of randomization or first dose of enzalutamide until date of PSA progression (pathological or therapeutic) (up to study completion date=28 Aug 2020, median duration: 14.82 months for "Enzalutamide", 8.80 months for "Active Surveillance")

  5. Percentage of Participants With Secondary Rise in Serum PSA

    Percentage of participants with secondary rise in serum PSA \> 25% baseline or \> 25% above nadir or absolute increase \>2 ng/mL were reported in this measure.

    Time frame: At the end of months 12, 24 and at the end of study (up to study completion date, 28 Aug 2020, approximately 50 months)

  6. Change From Baseline in Brief Fatigue Inventory (BFI) Questionnaire Composite Scores to Months 3, 6, 12, 18 and 24

    The BFI is a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions ask participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions ask participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A composite fatigue score was obtained by averaging all the items on the BFI, ranged between 0 to 10, with a higher BFI fatigue score indicating worse outcome. The composite BFI score was calculated only if at least 5 of the 9 items were answered.

    Time frame: Baseline, months 3, 6, 12, 18 and 24

  7. Change From Baseline in 12-Item Short Form Survey (SF-12) Questionnaire Composite Score to Months 6, 12, 18, 24 - Mental Component Summary

    SF-12 is a questionnaire that measures overall health related quality of life using 12 questions. The questions are then scored and weighted into 2 subscales, physical health and mental health. Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). Scores are transformed and ranges between 0 to 100; higher score indicates improvement.

    Time frame: Baseline, months 6, 12, 18 and 24

  8. Change From Baseline in SF-12 Questionnaire Composite Score to Months 6, 12, 18, 24 - Physical Component Summary

    SF-12 is a questionnaire that measures overall health related quality of life using 12 questions. The questions are then scored and weighted into 2 subscales, physical health and mental health. Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). Scores are transformed and ranges between 0 to 100; higher score indicates improvement.

    Time frame: Baseline, months 6, 12, 18 and 24

  9. Change From Baseline in The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Assessment Scores at Months 6, 12, 18 and 24

    The EPIC Hormonal Assessment was a questionnaire used to measure quality of life (QoL) issues in participants with prostate cancer. There were a total of 6 questions related to hormonal function such as hot flashes, breast tenderness, depression, lack of energy, weight fluctuation. The answers ranged from "more than once a day" to "rarely or never" (ranged from 1 to 5, corresponding standardized scores were 100, 75, 50, 25, 0), "no problem" to "big problem" (ranged from 0 to 4, corresponding standardized scores were 100, 75, 50, 25, 0). Score from each answer was converted into standardized score at each visit. Total score was calculated by taking average of standardized scores. Total score was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function.

    Time frame: Baseline, months 6, 12, 18 and 24

  10. Change From Baseline in EPIC Sexual Assessment Scores at Months 6, 12, 18 and 24

    EPIC Sexual Assessment: a questionnaire to measure QoL issues in participants with prostate cancer, included a total of 9 questions on sexual function as level of sexual desire, ability to have an erection, ability to reach orgasm, quality and frequency of erections, frequency of sexual intercourse. Answers ranged from "very poor" to "very good,"(ranged from 1 - 5, corresponding standardized scores:0, 25, 50, 75, 100), "none" to "enough"(ranged from 1 - 4, corresponding standardized scores:0, 33, 67, 100), "no problem" to "big problem"(ranged from 0 - 4, corresponding standardized scores:100, 75, 50, 25, 0), and "never" to "daily"(ranged from 1 - 5, corresponding standardized scores:100, 75, 50, 25, 0). Scores from each answer was converted into standardized score at each visit. Total score = calculated by taking average of standardized scores. Total score was measured on a scale ranged from 0 (worst) to 100 (best), higher scores = better sexual function and satisfaction.

    Time frame: Baseline, months 6, 12, 18 and 24

  11. Change From Baseline in EPIC Urinary Assessment Scores at Month 6, 12, 18 and 24

    EPIC urinary assessment: a questionnaire to measure QoL issues in participants with prostate cancer, included a total of 7 questions on urinary function as leaking urine, blood in urine, pain/burning on urination, urinary control and frequency. Answers ranged from "more than once a day" to "rarely or never"(scores from 1 - 5,corresponding standardized scores\[CSS\]:0, 25, 50, 75, 100), "no urinary control" to "full urinary control"(scores from 1 - 4,CSS:0, 33, 67, 100), "none" to "3 or more pads per day"(scores from 0 - 3, CSS:100, 67, 33, 0), "no problem" to "big problem"(scores from 0 - 4, CSS:100, 75, 50, 25, 0), and "no problem" to "big problem"(scores from 1 - 5, corresponding standardized score:100, 75, 50, 25, 0). Score from each answer was converted into a corresponding standardized score at each visit. Total score was calculated by taking average of standardized scores. Total score ranged from 0(worst) to 100(best), higher scores = better urinary function.

    Time frame: Baseline, months 6, 12, 18 and 24

  12. Change From Baseline in Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Scores at Months 6, 12, 18 and 24

    The MAX-PC was a questionnaire used to assess participants' feelings about prostate cancer and PSA tests. There were a total of 18 questions related to understanding how participants cope with aspects of their treatment and medical tests frequently involved in their care; questions such as strong feelings about prostate cancer, scared of PSA tests, trouble sleeping due to thoughts of prostate cancer, unable to plan for the future due to prostate cancer, fear of cancer getting worse. The answers range from "not at all" to "often" and "strongly disagree" to "strongly agree. Total score ranged from 0-54, an increase in the score indicates a worsened anxiety level.

    Time frame: Baseline, months 6, 12, 18 and 24

07

Results

Posted Nov 10, 2021

Participant flow

Adult participants with clinically localized, histologically proven prostate cancer diagnosed within 6 months of screening and had been on active surveillance were enrolled in this study. Participants were categorized as low risk or intermediate risk and had a minimum of 10 cores from transrectal ultrasound-guided prostate biopsy (multiparametric magnetic resonance imaging \[mpMRI\]-targeted versus non-mpMRI-targeted) done within 6 months prior to screening visit.

Participant flow — Overall Study
MilestoneEnzalutamideActive Surveillance
Started114113
Treated112113
Completed5842
Not completed5671
Withdrew: Participant moved out of state10
Withdrew: Discontinued due to planned surgery10
Withdrew: Withdrawal by subject1625
Withdrew: Protocol deviation45
Withdrew: Progressive disease2838
Withdrew: Lost to follow-up32
Withdrew: Death30
Withdrew: Adverse event01

Outcome measures

PrimaryTime to Prostate Cancer Progression

Time to cancer prostate progression (pathological or therapeutic): time (in months) from date of randomization until the date of cancer progression (pathological or therapeutic). Pathological progression: increase in primary or secondary Gleason pattern by greater than or equal (\>=) 1 or higher proportion of cancer positive cores (\>=15 percent \[%\] increase). Therapeutic progression: earliest occurrence of primary therapy for prostate cancer (prostatectomy/radiation/focal therapy/systemic therapy). Medians and 95% CIs were calculated with the Kaplan-Meier (KM) method. Participants with no cancer progression at the time of study completion, discontinuation or death were censored at the last assessment date. Participants switching therapy during the study were censored at the time of the initial therapy switch, and participants discontinuing therapy were censored at the time of study discontinuation.

Time frame:
From the date of randomization until the date of the cancer progression (pathological or therapeutic) (up to study completion date, 28 Aug 2020; approximately 50 months)
Reported as:
Median · Months
Time to Prostate Cancer Progression
MonthsEnzalutamideActive Surveillance
Time to Prostate Cancer ProgressionNA (36.14 to NA)NA (24.67 to NA)
Statistical analysis
  • Enzalutamide vs Active Surveillance · Log Rank · p = 0.016 (P-value was from a 2-sided stratified log-rank test.) · Hazard ratio (hr): 0.542 · 95% CI 0.330 to 0.892HR, 95% CI for HR:based on a Cox regression model assuming proportional hazards with treatment, prostate cancer risk,type of biopsy,baseline variables(as age, race), time since prostate cancer diagnosis as fixed effects and random effect of site.
SecondaryNumber of Participants With Adverse Events (AEs)

An AE: any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily had a causal relationship with treatment. An abnormality identified during a medical test: an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of investigator. An AE: serious if it resulted in any of the following outcomes: Death, was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs: assessed by investigator as AEs whose relationship to study drugs could not be ruled out.

Time frame:
From date of first dose of enzalutamide or randomization until end of study (up to study completion date, 28 Aug 2020; approximately 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsEnzalutamideActive Surveillance
Serious Adverse Events (SAEs)1910
non-SAEs10367
SecondaryPercentage of Participants Reported Negative Biopsies for Cancer

Percentage of Participants who reported negative biopsies for cancer were reported.

Time frame:
At the end of months 12 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Reported Negative Biopsies for Cancer
Percentage of participantsEnzalutamideActive Surveillance
At the end of month 1235.114.2
At the end of month 2419.012.0
Statistical analysis
  • Enzalutamide vs Active Surveillance · Regression, Logistic · p = 0.00 (P-value: Based on the exact binomial distribution from the logistic regression model.) · Odds ratio (or): 3.5 · 95% CI 1.76 to 6.92OR: from logistic regression model where fixed covariates=treatment group, prostate cancer risk, type of biopsy, age, race and time since prostate cancer diagnosis; random effects: site and subject. 95% CI: based on exact binomial distribution.
  • Enzalutamide vs Active Surveillance · Regression, Logistic · p = 0.289 (P-value: Based on the exact binomial distribution from the logistic regression model.) · Odds ratio (or): 1.6 · 95% CI 0.66 to 4.00OR: from logistic regression model where fixed covariates=treatment group, prostate cancer risk, type of biopsy, age, race and time since prostate cancer diagnosis; random effects: site and subject. 95% CI: based on exact binomial distribution.
SecondaryChange From Baseline in Percent of Cancer Positive Cores at Month 12 and 24

Percent positive cores were calculated using the number of systemically sampled prostate regions and any targeted regions with at least 1 positive core divided by the total number of systematically sampled regions and targeted regions. This implied that despite the number of samples within a given systematic or targeted region, any positive core indicated that region as positive.

Time frame:
Baseline, months 12 and 24
Reported as:
Mean · Percent of Cancer positive cores
Change From Baseline in Percent of Cancer Positive Cores at Month 12 and 24
Percent of Cancer positive coresEnzalutamideActive Surveillance
Change at month 12-14.2 ± 15.68-1.9 ± 14.70
Change at month 24-7.3 ± 17.74-0.8 ± 21.62
Statistical analysis
  • Enzalutamide vs Active Surveillance · Mixed Models Analysis · p = <0.001 (P-values: from differences of least squares means.Bonferroni-Holm was used in the primary hypothesis testing to adjust for multiplicity.) · Ls mean difference: -10.07 · 95% CI -14.79 to -5.34Mixed model repeated measure(MMRM) with treatment group, prostate cancer risk(low/intermediate), type of biopsy(mpMRI-targeted/non-mpMRI-targeted), visit, visit-by-treatment, baseline scores as fixed factors, site and participants as random factors.
  • Enzalutamide vs Active Surveillance · Mixed Models Analysis · p = 0.1063 (P-values: from differences of least squares means.Bonferroni-Holm was used in the primary hypothesis testing to adjust for multiplicity.) · Ls mean difference: -5.15 · 95% CI -11.40 to 1.11MMRM with treatment group, prostate cancer risk (low vs. intermediate), type of biopsy (mpMRI targeted vs. non mpMRI targeted), visit, visit-by-treatment and baseline scores were the fixed factors, and site and participants were the random factors.
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was defined as time in months from the date of randomization or first dose enzalutamide untill date of PSA progression (secondary rise in serum PSA \>=25% above baseline or \>=25% above nadir or absolute increase \>= 2 nanogram per mililiter \[ng/mL\]). Participants with no PSA progression at the time of trial completion, discontinuation or death were censored at the last assessment date. Additionally, participants switching therapy during the study were censored at the time of the initial therapy switch, and participants discontinuing therapy were censored at the time of study discontinuation. Medians and 95% CIs were calculated with the KM method.

Time frame:
From date of randomization or first dose of enzalutamide until date of PSA progression (pathological or therapeutic) (up to study completion date=28 Aug 2020, median duration: 14.82 months for "Enzalutamide", 8.80 months for "Active Surveillance")
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsEnzalutamideActive Surveillance
Time to Prostate-specific Antigen (PSA) Progression14.82 (14.75 to 14.95)8.80 (6.05 to 11.53)
Statistical analysis
  • Enzalutamide vs Active Surveillance · Log Rank · p = 0.032 (P-value: from a 2-sided, stratified log-rank test.) · Hazard ratio (hr): 0.714 · 95% CI 0.525 to 0.972HR and 95% CI for HR:based on Cox regression model assuming proportional hazards with treatment, prostate cancer risk, type of biopsy, baseline variables(as age, race), time since prostate cancer diagnosis as fixed effects and random effect of site.
SecondaryPercentage of Participants With Secondary Rise in Serum PSA

Percentage of participants with secondary rise in serum PSA \> 25% baseline or \> 25% above nadir or absolute increase \>2 ng/mL were reported in this measure.

Time frame:
At the end of months 12, 24 and at the end of study (up to study completion date, 28 Aug 2020, approximately 50 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Secondary Rise in Serum PSA
Percentage of participantsEnzalutamideActive Surveillance
At the end of month 1224.669.0
At the end of month 2492.092.8
At the end of study100.096.2
Statistical analysis
  • Enzalutamide vs Active Surveillance · Regression, Logistic · p = 0.000 (P-value:based on the exact binomial distribution from the logistic regression model.) · Odds ratio (or): 0.1 · 95% CI 0.08 to 0.26OR:from logistic regression model where treatment group, prostate cancer risk, type of biopsy, age, race and time since prostate cancer diagnosis were fixed covariates, site and participant were random effects. 95% CI:based on binomial distribution.
  • Enzalutamide vs Active Surveillance · Regression, Logistic · p = 0.807 (P-value: based on the exact binomial distribution from the logistic regression model.) · Odds ratio (or): 1.1 · 95% CI 0.37 to 3.53OR: from logistic regression model where treatment group, prostate cancer risk, type of biopsy, age, race and time since prostate cancer diagnosis were fixed covariates, site and participant were random effects. 95% CI:based on binomial distribution.
  • Enzalutamide vs Active Surveillance · Regression, Logistic · p = 0.931 (P-value:based on the exact binomial distribution from the logistic regression model.) · Odds ratio (or): 1.0 · 95% CI 0.50 to 2.15OR: from logistic regression model where treatment group, prostate cancer risk, type of biopsy, age, race and time since prostate cancer diagnosis were fixed covariates, site and participant were random effects. 95% CI:based on binomial distribution.
SecondaryChange From Baseline in Brief Fatigue Inventory (BFI) Questionnaire Composite Scores to Months 3, 6, 12, 18 and 24

The BFI is a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions ask participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions ask participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A composite fatigue score was obtained by averaging all the items on the BFI, ranged between 0 to 10, with a higher BFI fatigue score indicating worse outcome. The composite BFI score was calculated only if at least 5 of the 9 items were answered.

Time frame:
Baseline, months 3, 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in Brief Fatigue Inventory (BFI) Questionnaire Composite Scores to Months 3, 6, 12, 18 and 24
Units on a scaleEnzalutamideActive Surveillance
Change at month 30.7 ± 1.670.0 ± 1.32
Change at month 61.0 ± 2.03-0.1 ± 1.27
Change at month 121.2 ± 1.940.1 ± 1.32
Change at month 180.3 ± 1.43-0.2 ± 1.22
Change at month 240.5 ± 1.150.1 ± 1.27
SecondaryChange From Baseline in 12-Item Short Form Survey (SF-12) Questionnaire Composite Score to Months 6, 12, 18, 24 - Mental Component Summary

SF-12 is a questionnaire that measures overall health related quality of life using 12 questions. The questions are then scored and weighted into 2 subscales, physical health and mental health. Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). Scores are transformed and ranges between 0 to 100; higher score indicates improvement.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in 12-Item Short Form Survey (SF-12) Questionnaire Composite Score to Months 6, 12, 18, 24 - Mental Component Summary
Units on a scaleEnzalutamideActive Surveillance
Change at month 6-1.6 ± 5.94-0.1 ± 6.83
Change at month 12-2.3 ± 6.70-1.7 ± 6.84
Change at month 180.0 ± 6.18-0.5 ± 5.24
Change at month 24-0.3 ± 5.27-1.4 ± 7.29
SecondaryChange From Baseline in SF-12 Questionnaire Composite Score to Months 6, 12, 18, 24 - Physical Component Summary

SF-12 is a questionnaire that measures overall health related quality of life using 12 questions. The questions are then scored and weighted into 2 subscales, physical health and mental health. Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life). Scores are transformed and ranges between 0 to 100; higher score indicates improvement.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in SF-12 Questionnaire Composite Score to Months 6, 12, 18, 24 - Physical Component Summary
Units on a scaleEnzalutamideActive Surveillance
Change at month 6-2.8 ± 6.640.1 ± 5.45
Change at month 12-3.9 ± 6.73-0.9 ± 5.52
Change at month 18-3.9 ± 6.37-0.4 ± 4.37
Change at month 24-2.8 ± 5.96-1.6 ± 5.42
SecondaryChange From Baseline in The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Assessment Scores at Months 6, 12, 18 and 24

The EPIC Hormonal Assessment was a questionnaire used to measure quality of life (QoL) issues in participants with prostate cancer. There were a total of 6 questions related to hormonal function such as hot flashes, breast tenderness, depression, lack of energy, weight fluctuation. The answers ranged from "more than once a day" to "rarely or never" (ranged from 1 to 5, corresponding standardized scores were 100, 75, 50, 25, 0), "no problem" to "big problem" (ranged from 0 to 4, corresponding standardized scores were 100, 75, 50, 25, 0). Score from each answer was converted into standardized score at each visit. Total score was calculated by taking average of standardized scores. Total score was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Assessment Scores at Months 6, 12, 18 and 24
Units on a scaleEnzalutamideActive Surveillance
Change at month 62.2 ± 6.740.2 ± 3.51
Change at month 12-1.1 ± 6.770.4 ± 4.45
Change at month 18-1.7 ± 3.81-0.5 ± 4.29
Change at month 24-1.2 ± 4.930.6 ± 3.92
SecondaryChange From Baseline in EPIC Sexual Assessment Scores at Months 6, 12, 18 and 24

EPIC Sexual Assessment: a questionnaire to measure QoL issues in participants with prostate cancer, included a total of 9 questions on sexual function as level of sexual desire, ability to have an erection, ability to reach orgasm, quality and frequency of erections, frequency of sexual intercourse. Answers ranged from "very poor" to "very good,"(ranged from 1 - 5, corresponding standardized scores:0, 25, 50, 75, 100), "none" to "enough"(ranged from 1 - 4, corresponding standardized scores:0, 33, 67, 100), "no problem" to "big problem"(ranged from 0 - 4, corresponding standardized scores:100, 75, 50, 25, 0), and "never" to "daily"(ranged from 1 - 5, corresponding standardized scores:100, 75, 50, 25, 0). Scores from each answer was converted into standardized score at each visit. Total score = calculated by taking average of standardized scores. Total score was measured on a scale ranged from 0 (worst) to 100 (best), higher scores = better sexual function and satisfaction.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in EPIC Sexual Assessment Scores at Months 6, 12, 18 and 24
Units on a scaleEnzalutamideActive Surveillance
Change at month 6-26.7 ± 21.91-2.3 ± 15.34
Change at month 12-30.5 ± 23.31-2.9 ± 15.59
Change at month 18-9.5 ± 17.41-2.1 ± 15.91
Change at month 24-12.2 ± 18.35-3.7 ± 16.81
SecondaryChange From Baseline in EPIC Urinary Assessment Scores at Month 6, 12, 18 and 24

EPIC urinary assessment: a questionnaire to measure QoL issues in participants with prostate cancer, included a total of 7 questions on urinary function as leaking urine, blood in urine, pain/burning on urination, urinary control and frequency. Answers ranged from "more than once a day" to "rarely or never"(scores from 1 - 5,corresponding standardized scores\[CSS\]:0, 25, 50, 75, 100), "no urinary control" to "full urinary control"(scores from 1 - 4,CSS:0, 33, 67, 100), "none" to "3 or more pads per day"(scores from 0 - 3, CSS:100, 67, 33, 0), "no problem" to "big problem"(scores from 0 - 4, CSS:100, 75, 50, 25, 0), and "no problem" to "big problem"(scores from 1 - 5, corresponding standardized score:100, 75, 50, 25, 0). Score from each answer was converted into a corresponding standardized score at each visit. Total score was calculated by taking average of standardized scores. Total score ranged from 0(worst) to 100(best), higher scores = better urinary function.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in EPIC Urinary Assessment Scores at Month 6, 12, 18 and 24
Units on a scaleEnzalutamideActive Surveillance
Change at month 6-2.7 ± 10.260.7 ± 10.28
Change at month 12-4.2 ± 10.100.3 ± 10.98
Change at month 18-1.6 ± 9.550.2 ± 12.91
Change at month 24-1.6 ± 9.360.3 ± 13.47
SecondaryChange From Baseline in Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Scores at Months 6, 12, 18 and 24

The MAX-PC was a questionnaire used to assess participants' feelings about prostate cancer and PSA tests. There were a total of 18 questions related to understanding how participants cope with aspects of their treatment and medical tests frequently involved in their care; questions such as strong feelings about prostate cancer, scared of PSA tests, trouble sleeping due to thoughts of prostate cancer, unable to plan for the future due to prostate cancer, fear of cancer getting worse. The answers range from "not at all" to "often" and "strongly disagree" to "strongly agree. Total score ranged from 0-54, an increase in the score indicates a worsened anxiety level.

Time frame:
Baseline, months 6, 12, 18 and 24
Reported as:
Mean · Units on a scale
Change From Baseline in Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Scores at Months 6, 12, 18 and 24
Units on a scaleEnzalutamideActive Surveillance
Change at month 6-1.6 ± 6.23-0.5 ± 4.45
Change at month 12-0.8 ± 4.49-0.0 ± 4.52
Change at month 18-1.3 ± 4.86-0.6 ± 4.70
Change at month 24-1.4 ± 5.19-0.6 ± 3.78

Adverse events

Collected over From date of first dose of enzalutamide or randomization until end of study (up to study completion date, 28 Aug 2020, approximately 50 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide3/112 (2.7%)19/112 (17%)101/112 (90.2%)
Active Surveillance0/113 (0%)10/113 (8.8%)34/113 (30.1%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventEnzalutamideActive Surveillance
Myocardial infarctionCardiac disorders3/1120/113
Escherichia sepsisInfections and infestations2/1120/113
PneumoniaInfections and infestations2/1120/113
Arteriospasm coronaryCardiac disorders1/1120/113
Vertigo positionalEar and labyrinth disorders1/1120/113
EnteritisGastrointestinal disorders1/1120/113
Accidental deathGeneral disorders1/1120/113
Central cord syndromeInjury, poisoning and procedural complications1/1120/113
Hip fractureInjury, poisoning and procedural complications1/1120/113
Rib fractureInjury, poisoning and procedural complications1/1120/113
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEnzalutamideActive Surveillance
FatigueGeneral disorders62/1125/113
GynaecomastiaReproductive system and breast disorders42/1123/113
Nipple painReproductive system and breast disorders34/1120/113
Breast tendernessReproductive system and breast disorders29/1121/113
Erectile dysfunctionReproductive system and breast disorders22/1124/113
Upper respiratory tract infectionInfections and infestations11/1126/113
AlopeciaSkin and subcutaneous tissue disorders11/1120/113
ArthralgiaMusculoskeletal and connective tissue disorders10/1124/113
Back painMusculoskeletal and connective tissue disorders10/1124/113
Libido decreasedPsychiatric disorders10/1121/113

Baseline characteristics

The full analysis set (FAS) consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(Years)EnzalutamideActive SurveillanceTotal
Mean65.2 ± 8.1866.9 ± 7.2766.1 ± 7.77
Sex: Female, Male
Sex: Female, Male(Participants)EnzalutamideActive SurveillanceTotal
Female000
Male114113227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EnzalutamideActive SurveillanceTotal
Hispanic or Latino6612
Not Hispanic or Latino108107215
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EnzalutamideActive SurveillanceTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American81321
White10599204
More than one race000
Unknown or Not Reported101
Type of Biopsy
Type of Biopsy(Participants)EnzalutamideActive SurveillanceTotal
mpMRI-targeted272855
non-mpMRI-targeted8785172
Prostate Cancer Risk
Prostate Cancer Risk(Participants)EnzalutamideActive SurveillanceTotal
Low6160121
Intermediate5353106
08

Study locations

54 sites
  • Site US10034
    Birmingham, Alabama 35223, United States
  • Site US10024
    Homewood, Alabama 35209, United States
  • Site US10007
    Tucson, Arizona 85704, United States
  • Site US10055
    Tucson, Arizona 85741, United States
  • Site US10004
    Los Angeles, California 90048, United States
  • Site US10026
    Sacramento, California 95670, United States
  • Site US10010
    San Diego, California 92123, United States
  • Site US10051
    Aurora, Colorado 80045, United States
  • Site US10029
    Denver, Colorado 80211, United States
  • Site US10054
    Denver, Colorado 80220, United States
  • Site US10072
    Bradenton, Florida 34205, United States
  • Site US10057
    Lakeland, Florida 33805, United States
  • Site US10038
    Chicago, Illinois 60611, United States
  • Site US10062
    Chicago, Illinois 60612, United States
  • Site US10074
    Chicago, Illinois 60612, United States
  • Site US10018
    Glenview, Illinois 60026, United States
  • Site US10071
    Lake Barrington, Illinois 60010, United States
  • Site US10046
    Carmel, Indiana 46033, United States
  • Site US10009
    Jeffersonville, Indiana 47130, United States
  • Site US10037
    New Orleans, Louisiana 70112, United States
  • Site US10006
    Shreveport, Louisiana 71106, United States
  • Site US10001
    Towson, Maryland 21204, United States
  • Site US10032
    Boston, Massachusetts 02111, United States
  • Site US10008
    Troy, Michigan 48084, United States
  • Site US10069
    Lincoln, Nebraska 68516, United States
  • Site US10044
    Omaha, Nebraska 68114, United States
  • Site US10067
    Omaha, Nebraska 68130, United States
  • Site US10061
    Lebanon, New Hampshire 03756, United States
  • Site US10049
    Morristown, New Jersey 07962, United States
  • Site US10043
    Voorhees, New Jersey 08043, United States
  • Site US10068
    Brooklyn, New York 11215, United States
  • Site US10050
    Cheektowaga, New York 14225, United States
  • Site US10030
    Garden City, New York 11530, United States
  • Site US10028
    Poughkeepsie, New York 12601, United States
  • Site US10021
    Syracuse, New York 13210, United States
  • Site US10022
    Syracuse, New York 13210, United States
  • Site US10047
    Gastonia, North Carolina 28053, United States
  • Site US10045
    Cleveland, Ohio 44195, United States
  • Site US10015
    Middleburg Heights, Ohio 44130, United States
  • Site US10053
    Oklahoma City, Oklahoma 73104, United States
  • Site US10063
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Site US10052
    Lancaster, Pennsylvania 17604, United States
  • Site US10014
    Warwick, Rhode Island 02886, United States
  • Site US10019
    Myrtle Beach, South Carolina 29572, United States
  • Site US10011
    Nashville, Tennessee 37209, United States
  • Site US10056
    Dallas, Texas 75231, United States
  • Site US10036
    Houston, Texas 77027, United States
  • Site US10035
    San Antonio, Texas 78229, United States
  • Site US10058
    Richmond, Virginia 23235, United States
  • Site US10017
    Milwaukee, Wisconsin 53226, United States
  • Site CA15005
    Abbotsford, British Columbia V2S 3N6, Canada
  • Site CA15004
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Site CA15001
    Toronto, Ontario M4N3M5, Canada
  • Site CA15003
    Toronto, Ontario M5G2M9, Canada
09

References and documents

Publications

  • Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1128-1136. doi: 10.1001/jamaoncol.2022.1641. Erratum In: JAMA Oncol. 2022 Aug 01;8(8):1225. doi: 10.1001/jamaoncol.2022.3577. PubMed 35708696 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Aug 2020, 50 months.

Results were first posted in Nov 2021, 1 year 2 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 50 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2016
First posted
Jun 15, 2016
StartActual
Jun 9, 2016
Primary completionActual
Aug 28, 2020
CompletionActual
Aug 28, 2020
Results first posted
Nov 10, 2021
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02799745
Collaborators
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Jun 9, 2016
Primary completion
Aug 28, 2020
Completion
Aug 28, 2020
Results posted
Nov 10, 2021
Last update
Dec 6, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion